VivoSeq
Other

Liquid Biopsy

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Liquid Biopsy is an early-stage landscape with 0 programs across 1 company. The most active players are Hellenic Oncology Research Group.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hellenic Oncology Research Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Unknown status2 · 33%
Active, not recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
Recruiting·AAzienda USL Reggio Emilia - IRCCS·Phase 3·NCT04776655·280 enrolled
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
Active, not recruiting·FFundación GECP·Phase 2·NCT04223596·33 enrolled
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
Completed·KKonkuk University Medical Center·Phase 2·NCT03228277·25 enrolled
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Completed·—·Phase 2·NCT03394118·63 enrolled
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Unknown status·FFudan University·N/A·NCT05188911·30 enrolled
Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
Unknown status·HHellenic Oncology Research Group·Phase 2·NCT02771314·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)